Genmab — Juni 2022
-
Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody
-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) -
Jeg holder en lille fest for mig selv
-
Thx´
-
-
Man vurderer, at markedet skal informeres om væsentlige forhold
-
Da man ansøgte Tisotumab Vedotin kom selskabsmeddelelsen først da FDA havde accepteret ansøgningen.
-
Fedt.
-
Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody
-CD3xCD20) for the https://www.proinvestor.com/investornyt/844797/genmab-to-submit-biologics-license-application-to-us-food-and-drug-administration-for-epcoritamab-duobody-cd3xcd20-for-the -
FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib) https://www.healio.com/news/hematology-oncology/20220630/fda-warns-about-potential-elevated-risk-for-death-with-blood-cancer-therapy-durvelisib
https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-possible-increased-risk-death-and-serious-side-effects-cancer-drug-copiktra#:~:text=The U.S. Food and Drug,found in the lymph nodes.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind